Arcus Development Group Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Arcus Development Group in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Arcus Development Group vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Arcus Development Group | - | - | - | - | - | - | - |
| Zonte Metals Inc. | -9.320% | -4.065% | 80.153% | 227.778% | 120.561% | 105.217% | 1.724% |
| TomaGold Corp | 6.980% | -33.333% | 100.000% | 1128.571% | 75.510% | 75.510% | -5.495% |
| Golconda Gold Ltd. | -1.790% | -12.605% | 32.484% | - | 32.484% | - | - |
News
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return
On Dec. 4, 2025, Juan C. Jaen, President of Arcus Biosciences (NYSE:RCUS), disposed of 82,997 shares in an open-market transaction via an indirect holding, generating a transaction value of
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
Juan C. Jaen, the president of Arcus Biosciences (NYSE:RCUS), sold 96,859 shares in multiple open-market transactions on Tuesday and Wednesday, according to an SEC Form 4 filing.
The transaction
Arcus (RCUS) Q2 Revenue Jumps 310%
Arcus Biosciences (NYSE:RCUS), a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both